Cargando…

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

OBJECTIVES: To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod. METHODS: This is a substudy of a prospective multicenter study on SAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palomares Cabeza, Virginia, Kummer, Laura Y.L., Wieske, Luuk, Hagen, Ruth R., Duurland, Mariel, Konijn, Veronique A.L., van Dam, Koos P.J., Stalman, Eileen W., van de Sandt, Carolien E., Boekel, Laura, Verstegen, Niels J.M., Steenhuis, Maurice, Rispens, Theo, Tas, Sander W., Wolbink, Gertjan, Killestein, Joep, Kuijpers, Taco W., van Ham, S. Marieke, Eftimov, Filip, Brinke, Anja ten, van Kempen, Zoé L.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical/Scientific Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082763/ https://www.ncbi.nlm.nih.gov/pubmed/35523569 http://dx.doi.org/10.1212/NXI.0000000000001178

Ejemplares similares

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
por: van Dam, Koos P. J., et al.
Publicado: (2022)

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2021)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
por: Wieske, Luuk, et al.
Publicado: (2022)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8 (+) T memory cells in convalescent COVID‐19 donors
por: van den Dijssel, Jet, et al.
Publicado: (2022)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
por: van Dam, Koos P.J., et al.
Publicado: (2023)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
por: van Dam, Koos P. J., et al.
Publicado: (2023)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
por: Wieske, Luuk, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells
por: Marsman, Casper, et al.
Publicado: (2022)

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Minimalistic In Vitro Culture to Drive Human Naive B Cell Differentiation into Antibody-Secreting Cells
por: Unger, Peter-Paul A., et al.
Publicado: (2021)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pgadp30n8v10m45b5eokdl8p29